Matt Lastrapes

Matt Lastrapes

Auto-generated profile, based on publicly available information

Matt Lastrapes

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
CAChristopher Alvarez-Breckenridge
Christopher Alvarez-Breckenridge
SMSamuel C. Markson
Samuel C. Markson
JSJackson H. Stocking
Jackson H. Stocking
NNNaema Nayyar
Naema Nayyar
MLMatt Lastrapes
Matt Lastrapes
SCScott L. Carter
Scott L. Carter
Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system progression is frequently an end stage of the disease. Immune checkpoint inhibitors (ICI) provide a clinical opportunity against MBM; however, the MBM tumor microenvironment (TME) has not been fully elucidated in the context of ICI. To dissect unique elements of the MBM TME and correlates of MBM response to ICI, we collected 32 fresh MBM and performed single-cell RNA sequencing of the MBM TME and T-cell receptor clonotyping on T cells from MBM and matched blood and extracranial lesions. We observed myeloid phenotypic heterogeneity in the MBM TME, most notably multiple distinct neutrophil states, including an IL8-expressing population that correlated with malignant cell epithelial-to-mesenchymal transition. In addition, we observed significant relationships between intracranial T-cell phenotypes and the distribution of T-cell clonotypes intracranially and peripherally. We found that the phenotype, clonotype, and overall number of MBM-infiltrating T cells were associated with response to ICI, suggesting that ICI-responsive MBMs interact with peripheral blood in a manner similar to extracranial lesions. These data identify unique features of the MBM TME that may represent potential targets to improve clinical outcomes for patients with MBM.

2 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
YDYibo Dai
Yibo Dai
AKAnne Knisely
Anne Knisely
MYMitsutake Yano
Mitsutake Yano
MDMinghao Dang
Minghao Dang
EHEmily M. Hinchcliff
Emily M. Hinchcliff
AJAmir A. Jazaeri
Amir A. Jazaeri
Immune checkpoint blockade (ICB) therapy is effective against many cancers, although resistance remains a major issue and new strategies are needed to improve clinical outcomes1,2,3,4,5. Here we studied ICB response in a cohort of patients with ovarian clear cell carcinoma—a cancer type that poses considerable clinical challenges and lacks effective therapies6,7,8. We observed significantly prolonged overall survival and progression-free survival in patients with tumours with PPP2R1A mutations. Importantly, our findings were validated in additional ICB-treated patient cohorts across multiple cancer types. Translational analyses from tumour biopsies demonstrated enhanced IFNγ signalling, and the presence of tertiary lymphoid structures at the baseline, as well as enhanced immune infiltration and expansion of CD45RO+CD8+ T cells in the tumour neighbourhood after ICB treatment in PPP2R1A-mutated tumours. Parallel preclinical investigations showed that targeting PPP2R1A (by pharmacological inhibition or genetic modifications) in in vitro and in vivo models was associated with improved survival in the setting of treatment with several forms of immunotherapy, including chimeric antigen receptor (CAR)-T cell therapy and ICB. The results from these studies suggest that therapeutic targeting of PPP2R1A may represent an effective strategy to improve patient outcomes after ICB or other forms of immunotherapy, although additional mechanistic and therapeutic insights are needed.

5 September 2025 in Nature
Verified
Journal Article
Open access
PDF file
YDYibo Dai
Yibo Dai
AKAnne Knisely
Anne Knisely
MYMitsutake Yano
Mitsutake Yano
MDMinghao Dang
Minghao Dang
EHEmily M. Hinchcliff
Emily M. Hinchcliff
AJAmir A. Jazaeri
Amir A. Jazaeri

4 April 2023
Verified
Other
Open access
CAChristopher Alvarez-Breckenridge
Christopher Alvarez-Breckenridge
SMSamuel C. Markson
Samuel C. Markson
JSJackson H. Stocking
Jackson H. Stocking
NNNaema Nayyar
Naema Nayyar
MLMatt Lastrapes
Matt Lastrapes
SCScott L. Carter
Scott L. Carter
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition

4 April 2023
Verified
Other
Open access
CAChristopher Alvarez-Breckenridge
Christopher Alvarez-Breckenridge
SMSamuel C. Markson
Samuel C. Markson
JSJackson H. Stocking
Jackson H. Stocking
NNNaema Nayyar
Naema Nayyar
MLMatt Lastrapes
Matt Lastrapes
SCScott L. Carter
Scott L. Carter
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition

4 April 2023
Verified
Other
Open access
CAChristopher Alvarez-Breckenridge
Christopher Alvarez-Breckenridge
SMSamuel C. Markson
Samuel C. Markson
JSJackson H. Stocking
Jackson H. Stocking
NNNaema Nayyar
Naema Nayyar
MLMatt Lastrapes
Matt Lastrapes
SCScott L. Carter
Scott L. Carter
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition